Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.
Composition:
1 ml of solution contains 1 mg olopatadine (as hydrochloride). The preparation contains benzalkonium chloride.
Action:
A strong and selective antiallergic / antihistamine drug. Olopatadine antagonizes the action of histamine and prevents the histamine-induced production of cytokines by human conjunctival epithelial cells. Data from testsin vitro they suggest that it can affect the human conjunctival mast cells by inhibiting the production of inflammatory mediators. In patients with patent nasal-lacrimal tract, local administration of olopatadine to the eye reduces the severity of subjective and subjective nasal symptoms, which often coexist with seasonal allergic conjunctivitis. Olopatadine does not cause clinically significant changes in pupil diameter. When administered topically, it is absorbed into the bloodstream to a minimum.
Contraindications:
Hypersensitivity to olopatadine or to any of the excipients.
Precautions:
If symptoms of serious adverse reactions or hypersensitivity reactions occur, the drug should be discontinued. The benzalkonium chloride contained in the preparation may cause punctate and / or toxic ulcerative corneal defects; Patients who frequently or prolonged use of the preparation and who have dry eye or diseases in which corneal function is impaired should be carefully monitored. Do not instill the product while wearing contact lenses. Wait 10-15 minutes after instillation of the preparation for contact lenses.
Pregnancy and lactation:
Exercise caution when prescribing to pregnant women. It is not known if topical administration in humans may result in systemic absorption sufficient to detect detectable concentrations of olopatadine in milk - use is not recommended during breastfeeding.
Side effects:
Common: headache, disturbances of taste, eye, eye irritation, dry eye, unusual sensations in the eyes, dry nose, tiredness. Uncommon: rhinitis, dizziness, decreased sensation of the touch, corneal erosion, corneal epithelium abnormalities, corneal epithelial disorder, corneal keratitis, keratitis, corneal spots, eye discharge, photophobia, blurred vision, reduced visual acuity, blepharospasm eye discomfort, ocular pruritus, clots on the conjunctiva, feeling of a foreign body in the eyes, increased tearing, eyelid pruritus, eyelid flushing, eyelid edema, eyelid disease, conjunctival congestion, ocular congestion, contact dermatitis, skin burning sensation, dry skin . After placing on the market (frequency unknown): corneal edema, conjunctivitis, swelling of the eye, swollen eye, mydriasis, blurred vision, scabbing on the eyelid edges, hypersensitivity reactions, shortness of breath, drowsiness, facial edema, dermatitis, erythema, nausea, vomiting , sinusitis, muscle weakness, malaise.
Dosage:
Adults and children ≥ 3 years: 1 drop into the conjunctival sac of the affected eye (eyes) 2 times a day (with an 8-hour break between instillation of subsequent doses). If necessary, treatment can be continued for up to 4 months. For concomitant treatment with other topical ophthalmic medications, a 5-10 minute interval should be maintained between the administration of the Next medication.Special groups of patients. There is no need to change the dosage in elderly patients as well as in patients with impaired renal or hepatic function.
(C)
